Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C

TA106 Hepatitis C - peginterferon alfa and ribavirin: review decision - December 2013 information

TA106 Hepatitis C - peginterferon alfa and ribavirin: Appendix A - decision paper presented to the Institute's Guidance Executive (PDF 112 KB)

TA106 Hepatitis C - peginterferon alfa and ribavirin: review proposal - October 2013 information

TA106 Hepatitis C - peginterferon alfa and ribavirin: - Appendix A - provisional matrix of stakeholders (PDF 100 KB)

TA106 Hepatitis C - peginterferon alfa and ribavirin: Appendix B - GE Proposal Paper September 2013 (PDF 534 KB)

Review decision, August 2008  information

Review decision - March 2008: table of comments (PDF 135 KB)

Review proposal, March 2008 information

Thousands more people with hepatitis C to benefit from latest NICE guidance on drug treatments information

Thousands more people with hepatitis C to benefit from latest NICE guidance on drug treatments (PDF 42 KB)

Hepatitis C (mild) - interferon alfa (pegylated and non-pegylated) and ribavirin (review): Final appraisal determination information

Hepatitis C (mild) - interferon alfa (pegylated and non-pegylated) and ribavirin (review): Final appraisal determination (PDF 105 KB)

Response to consultee and commentator comments on the ACD (PDF 90 KB)

Consultee and commentator comments on the ACD

Association of Nurses in Substance Abuse (PDF 26 KB)

British Society of Gastroenterology (PDF 19 KB)

Department of Health Development Agency (PDF 44 KB)

Foundation of Liver Research (PDF 31 KB)

Haemophilia Society (PDF 42 KB)

Hepatitis C Trust (PDF 32 KB)

MRC Clinical Trials Unit (PDF 22 KB)

NHS Quality Improvement Scotland (PDF 26 KB)

Roche Products Limited (PDF 44 KB)

Royal College of General Practitioners (PDF 58 KB)

Royal College of Nursing (PDF 14 KB)

Royal College of Pathologists (PDF 52 KB)

Schering-Plough Ltd (PDF 37 KB)

Welsh Assembly Government (PDF 42 KB)

Welsh Assembly Government attachment (PDF 14 KB)

Foster (PDF 75 KB)

Hepatitis C (mild) - interferon alfa (pegylated and non-pegylated) and ribavirin (review): Appraisal consultation document  information

Final scope (PDF 35 KB)

Evaluation Report

Hepatitis C - peginterferon alfa and ribavirin: assessment report (PDF 1.21 MB)

Overview (PDF 75 KB)

Consultee and commentator comments on the assessment report

Royal College of Pathologists (2) (PDF 40 KB)

Schering Plough Ltd (PDF 42 KB)

CPAP ACD - Consultee and commentator comments: Royal College of Nursing (PDF 12 KB)

Roche Products Ltd (PDF 25 KB)

NHS Quality Improvement Scotland (PDF 16 KB)

MRC Clinical Trials Unit (PDF 30 KB)

Mainliners (PDF 32 KB)

Haemophilia Alliance and UK Haemophilia Centre (PDF 13 KB)

British Society of Gastroenterology (PDF 36 KB)

British Association for the Study of the Liver (PDF 13 KB)

Manufacturer submissions (executive summary only)

Schering-Plough Ltd (2) (PDF 19 KB)

Roche Products Ltd (2) (PDF 42 KB)

Non manufacturer submissions

Royal College of Pathologists (PDF 40 KB)

Anaemia (cancer-treatment induced) - erythropoietin (alpha and beta) and darbepoetin: Appraisal consultation - Royal College of Physicians (PDF 22 KB)

Royal College of Nursing (2) (PDF 13 KB)

Hepatitis C Trust (PDF 45 KB)

Haemophilia Society (PDF 41 KB)

Expert written personal statements

Morris (PDF 43 KB)

Maulayah (PDF 26 KB)

Gore (PDF 24 KB)

Foster (PDF 20 KB)

Final Protocol (PDF 75 KB)

Response to consultee and commentator comments on the draft scope (PDF 41 KB)

Response to consultee and commentator comments on the provisional matrix of consultees and commentators (PDF 22 KB)

Archive Draft scope (PDF 33 KB)

Archive Provisional matrix of consultees and commentators (PDF 30 KB)